Abstract

DuPont de Nemours Inc will report quarterly results on August 04, 2026, Pre-Market; the preview below compiles market forecasts, last quarter performance, and institutional commentary to frame expectations.

Market Forecast

Consensus points to a downshift this quarter: revenue is projected at 1.81 billion US dollars with an estimated year-over-year decline of 44.06%, EPS is forecast at 1.77 with a year-over-year decline of 44.62%, and EBIT is expected near 0.35 billion US dollars with a 48.31% year-over-year decline. Company-level margins are anticipated to stay constrained by mix; the setup implies continued pressure on adjusted EPS and a net margin profile that tracks weaker volumes and pricing versus last year. Management’s focus on portfolio quality and operational discipline suggests the gross margin should hold up relative to volumes, while net margin remains tied to cost absorption and pricing discipline.

The company’s main businesses are diversified industries at 0.88 billion US dollars and healthcare and water technology at 0.81 billion US dollars. The most promising segment for incremental contribution is healthcare and water technology, supported by secular demand for filtration, bioprocessing, and water treatment; this business is positioned to show relatively better resilience on a year-over-year basis compared with cyclical diversified industrial exposures.

Last Quarter Review

The prior quarter delivered 1.68 billion US dollars of revenue, a gross profit margin of 35.81%, GAAP net profit attributable to shareholders of 0.16 billion US dollars, a net profit margin of 9.58%, and adjusted EPS of 1.65, reflecting a 46.60% year-over-year decline. Quarter on quarter, net profit attributable to shareholders increased by 227.78%, aided by improved cost control and mix stabilization relative to the immediately preceding period.

Within the portfolio, operational execution supported stable gross economics despite sharp top-line contraction year over year. By business line, diversified industries contributed 0.88 billion US dollars and healthcare and water technology contributed 0.81 billion US dollars, with the latter offering steadier demand from utilities, life sciences, and process end-markets.

Current Quarter Outlook

Main Businesses and Margin Shape

Management’s recent trajectory indicates a conscious tradeoff between volume and price, designed to protect gross margin while market demand remains uneven. With consensus revenue tracking down more than 40% from the year-ago period, the company’s ability to preserve a mid-30s gross margin hinges on procurement savings, footprint optimization, and disciplined pricing in less commoditized niches. The expected EBIT step-down suggests operating leverage remains negative at current volumes, so incremental margin likely trends below historical averages and puts a cap on adjusted EPS recovery until volumes stabilize.

Healthcare and Water Technology as the Relative Bright Spot

Healthcare and water technology, at approximately 0.81 billion US dollars last quarter, is positioned to be the relatively more resilient growth engine this quarter. Demand for water treatment membranes, bioprocessing consumables, and filtration remains underpinned by regulatory standards and ongoing infrastructure replacement cycles. Even if headline revenue is down year over year, this segment’s pricing power and consumables mix can support better drop-through versus more cyclical subsegments, narrowing the spread between gross and net margin in the consolidated profile.

Stock Price Sensitivities for This Print

Stock reaction is likely to hinge on three items: revenue trajectory versus the 1.81 billion US dollars bar, the durability of gross margin around the mid-30s level, and management’s commentary on order trends into the second half. A narrower-than-feared EPS decline, achieved via cost containment and mix, would be taken positively even if sales remain soft. Conversely, incremental pricing pressure or slippage in margin could overpower any small top-line beats, re-centering investor focus on cyclical risk rather than portfolio defensiveness.

Analyst Opinions

Most institutional commentary leans cautious into the release, emphasizing downside skew to volumes and the risk that operating leverage restrains near-term EPS. Analysts highlighting the healthcare and water technology exposure view it as a stabilizer but not enough to offset the year-over-year revenue compression implied by consensus. The prevailing view is that guidance tone and order momentum will matter more than a minor beat or miss, with valuation support requiring clearer evidence of recovery in diversified industrial end-markets.